I. Oomen MD
- PhD Candidate
- Main activities
- Pediatric Hematology
- Focus of research
Patients with severe hemophilia A can be effectively treated by intravenous administration of the deficient coagulation factor VIII (FVIII). However, in about 25-35% of patients, treatment is complicated by the development of neutralizing alloantibodies, called inhibitors. Eradication of inhibitors can be achieved by repeated administration of high-dose therapeutic FVIII, called immune tollerance induction (ITI). Unfortunately, this approach is only effective in about 70% of patients.
GO ITI Study Genetic determinants of the Outcome of Immune Tolerance Induction therapy in patients with severe hemophilia A and inhibitors.
The aim of this study is to identify genetic determinants that are associated with successful immune tolerance induction in patients with hemophilia A and inhibitors.
GRIP Study The role of Fc Gamma Receptors in Immune tolerance to factor VIII Protein.
This project aims to determine how the interaction of FVIII immune complexes with FcyRs directs the response of dendritic cells.